story on inside buisness, page-4

Indeed:

clear indication that the US move is to off-load a management team that has failed to sell BIOTA and wipe their hands off them as well as pandering to a US cornerstone investor

NO reason that sufficient funds/Insto's can't be found on the much more liquid Aussie markets.

Clear spelling out of the disastrous GSK deal for Relenza and opportunities lost like actually "selling" of the BARDA grant here in Australia to SH and funds.

and that is the consensus between Alan and editors of the Australina and AFR - and they should know a thing or two......................... however the AFR editor can see the benefit re BARDA for move

Looks like some "cute" questions will have to be answered at the Sydney meeting !